The Drug That Might Pay For Itself
The Congressional Budget Office scored Medicare coverage of anti-obesity medications as adding about $35.5 billion to deficits from 2026 to 2034, with savings offsetting roughly nine cents on the dollar. The episode keeps the federal cash ledger apart from the value ledger, then shows the price falling about 71 percent in November 2025 without any re-score. It offers no medical advice and takes no view on whether anyone should take these drugs.
Who's who
- Noelia DuchovnyCBO health analyst who described the office's scoring method
- Jin H. HwangUniversity of Chicago lead author of the cost-effectiveness and fiscal-impact analyses
- David D. KimUniversity of Chicago co-author of the modeling papers
- Sean D. SullivanLead author of the 2026 re-estimate at new prices
- Mehmet OzCMS Administrator who reported 250,000 sign-ups for the Medicare bridge
- Christian S. HendershotLead author of a 2025 phase 2 alcohol trial with 48 participants
- William WangCase Western researcher behind the 2024 tobacco-use observational study
Where it happens
- United States+16 more episodesSetting of the Medicare coverage and pricing debate
- Copenhagen, Denmark+2 more episodesSite of the 108-person alcohol trial published in The Lancet
Timeline
- October 8, 2024CBO scores Medicare coverage of anti-obesity drugs at about $35.5 billion in added deficits.
- March 14, 2025A Chicago analysis puts the cost per quality-adjusted life year far above the $100,000 bar.
- November 6, 2025Arrangements set injectables at $245 a month for Medicare and Medicaid.
- November 25, 2025CMS publishes a negotiated 2027 price of $274 per 30-day supply, 71 percent below the 2024 list.
- July 1, 2026The temporary Medicare GLP-1 Bridge begins operating.
- July 29, 2026CMS reports 250,000 beneficiaries have signed up.
Still debated
Whether semaglutide clears $100,000 per quality-adjusted life year at the new price is unresolved, and rescaling a model is not re-running it. CBO and a Chicago team differ threefold on offsets yet agree costs exceed savings. The $245 arrangement is not a statute, and the addiction trials are short and selected.
